Interferon-free treatment regimens for hepatitis C: are we there yet?
Pratima
P
Sharma
Anna S
AS
Lok
D000621:Aminoisobutyric Acids; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D016174:Hepacivirus / Q000187:drug effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007930:Leucine / Q000031:analogs & derivatives; D008297:Male; D009842:Oligopeptides / Q000627:therapeutic use*; D011392:Proline / Q000031:analogs & derivatives; D011804:Quinolines; D012324:RNA-Dependent RNA Polymerase / Q000037:antagonists & inhibitors*; D012254:Ribavirin / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
D000621:Aminoisobutyric Acids; D000998:Antiviral Agents; D009842:Oligopeptides; D011804:Quinolines; D013844:Thiazoles; D012254:Ribavirin; C552340:faldaprevir; D011392:Proline; D012324:RNA-Dependent RNA Polymerase; D007930:Leucine